BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer
BeiGene has announced that its Tizveni (tislelizumab) has received approval from the European Commission (EC) to treat non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. Currently the third most common cancer …